Navigation Links
Mutated Kras spins a molecular loop that launches pancreatic cancer
Date:1/26/2012

HOUSTON Scientists have connected two signature characteristics of pancreatic cancer, identifying a self-perpetuating "vicious cycle" of molecular activity and a new potential target for drugs to treat one of the most lehal forms of cancer.

The research, reported in the journal Cancer Cell and led by scientists at The University of Texas MD Anderson Cancer Center, connected the molecular dots between:

  • Mutated versions of Kras, a gene that acts as a molecular on-off switch but gets stuck in the "on" position when mutated.
  • Heightened activity of a protein complex called NF-B that controls activation of genes.

"Kras is mutated in 80 to 95 percent of pancreatic ductal adenocarcinomas, and is the most frequent mutation among all cancers," said senior author Paul Chiao, Ph.D., professor in MD Anderson's Department of Molecular and Cellular Oncology.

About 42,000 new cases of pancreatic ductal adenocarcinoma are diagnosed in the United States each year. Estimates vary, but the 5-year survival rate has been 1 to 3 percent for decades and median survival after diagnosis is six months, the researchers note.

Interleukin-1α is a new potential drug target

"There have been many attempts to inhibit mutated Kras, but it's an elusive target that so far has defied treatment," Chiao said. "So if we can't hit Kras, maybe we can target one of its downstream genes. This research identifies some of those genes and suggests that interleukin-1apha (IL-1α) is a potential therapeutic target."

Chiao and colleagues identified IL-1α as a crucial player in a feed-forward loop that:

  • Begins with mutationally activated Kras triggering a chain reaction that induces IL-1α expression;
  • This in turn activates NF-κB via the protein kinase IKK2/β, which blocks the inhibitor of NF-κB.
  • In the cell nucleus, NF-κB oversees gene transcription and regulates a number of inflammation-promoting genes, including IL-1α.
  • IL-1α and another protein called p62 activate NF-κB which in turn cycles back to perpetuate the loop by activating its activators.

"It's a vicious cycle," Chiao said. The overactive NF-κB fuels pancreatic cancer by activating genes that promote inflammation, the growth of new blood vessels and block programmed cell death.

Chiao has three research grants from the National Cancer Institute to study pancreatic cancer. "We study signaling transduction pathways to try to find out why it's such a bad disease and to find a weak point for targeted therapy," he said.

In the Cancer Cell paper, the authors conclude: "Our findings suggest that the prime mover responsible for cancer-related inflammatory response and the development of pancreatic intraepithelial neoplasia (precancerous lesions) and pancreatic ductal adenocarcinoma is the mutant Kras-initiated constitutive activation of NF-κB."

This process, they further noted, creates a pro-tumor microenvironment by promoting inflammation, creation of new blood vessels and tissue repair that is similar to conditions found in inherited pancreatitis, inflammation of the pancreas that is linked to the development of cancer.

Kras mutation, IL-1α, NF-κB go together with poor survival

The team analyzed mouse and human tumors and mouse strains with mutated Kras expressed in their pancreases. In a series of experiments they found:

  • Active IKK2/ the activator of NF-κB was required for the Kras-mutated mice to develop either pancreatic cancer or precancerous legions.
  • Deletion of IKK2/Beta interrupted Kras-stimulated inflammation and cell proliferation, suggesting that chronic inflammation is a key factor in promoting pancreatic cancer development.
  • Microarray profiles of gene expression showed that several NF-κB-regulated inflammatory genes were present in high levels in mice with mutated Kras and active IKK2/ but only found at lower levels in mice with IKK2/ knocked out.
  • In human pancreatic tumors, high expression of the same inflammatory genes in the mutated Kras mice were associated with positive lymph node status, high-risk, late tumor stage and poor survival.
  • Expression of several genes regulated by NF-κB progressed from low levels in normal pancreases to higher levels in precancerous lesions and tumors, including IL-α.
  • IL-1α was known to be both a target of and an inducer of NF-κB, but its expression had not previously been connected to mutated Kras. The team found that downstream targets of Kras, including IL-1, are interrupted when IKK2/β is inactivated.
  • Analysis of 14 human pancreatic cancer tumor samples showed that overexpression of IL-1α, the presence of Kras mutation and the activation of NF-κB are correlated and are associated with poor survival.
  • Continued activation of NF-κB and its gene transcription activity are sustained by IL-1α and p62.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Single Lung Tumor Contains 50,000 Mutated Genes
2. Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene
3. Mouse model confirms mutated proteins role in dementia
4. When leukemia returns, gene that mediates response to key drug often mutated
5. Mutated gene found in dog disease the same in humans, MU researchers find
6. Molecular pathways linked to sex, age affect outcomes in lung cancer
7. SNMs Conjoint Mid-Winter Meetings continue to advance molecular imaging
8. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
9. The Association for Molecular Pathology celebrates ruling in DNA patent case
10. USC researchers discover new molecular subtype of brain cancer
11. Molecular discovery points to new therapies for brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mutated Kras spins a molecular loop that launches pancreatic cancer
(Date:10/13/2017)... Little Rock, AR (PRWEB) , ... October 13, ... ... owned firm with locations throughout Arkansas that offers insurance and financial preparation services, ... to benefit the Rock City Rescue organization. , Rock City Rescue is a ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
Breaking Medicine Technology: